Literature DB >> 2647706

The clinical evaluation of antibacterial drugs. Report of a Working Party of the British Society of Antimicrobial Chemotherapy.

.   

Abstract

Mesh：

Substances：

Year:  1989        PMID： 2647706

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN： 0305-7453            Impact factor:   5.790


× No keyword cloud information.
  8 in total

Review 1.  The implications for Europe of revised FDA guidelines for clinical trials with anti-infective agents.

Authors:  D N Gilbert; T R Beam; C M Kunin
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1990-07       Impact factor: 3.267

Review 2.  Regulatory requirements for clinical evaluation of antimicrobial agents.

Authors:  W Christ
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1990-07       Impact factor: 3.267

3.  [Documentation and assessment of adverse drug effects with ofloxacin as an example].

Authors:  B Esch; N Paeschke; W Christ; G Kreutz
Journal:  Infection       Date:  1991       Impact factor: 3.553

4.  [Use-risk consideration of anti-infective agents from the point of view of the licensing authority].

Authors:  W Christ; B Esch
Journal:  Infection       Date:  1991       Impact factor: 3.553

Review 5.  The design of clinical trials with antibiotics.

Authors:  S R Norrby
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1990-07       Impact factor: 3.267

Review 6.  The clinical evaluation of antibacterial drugs: guidelines of the British Society for Antimicrobial Chemotherapy.

Authors:  R G Finch
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1990-07       Impact factor: 3.267

7.  Design of clinical trials in patients with urinary tract infections.

Authors:  S R Norrby
Journal:  Infection       Date:  1992       Impact factor: 3.553

8.  Randomized controlled trial of sequential intravenous (i.v.) and oral moxifloxacin compared with sequential i.v. and oral co-amoxiclav with or without clarithromycin in patients with community-acquired pneumonia requiring initial parenteral treatment.

Authors:  R Finch; D Schürmann; O Collins; R Kubin; J McGivern; H Bobbaers; J L Izquierdo; P Nikolaides; F Ogundare; R Raz; P Zuck; G Hoeffken
Journal:  Antimicrob Agents Chemother       Date:  2002-06       Impact factor: 5.191
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.